NCT06505278View on ClinicalTrials.gov

The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening

Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER